Arca
Skip to content
Tools
Tools

Label Changes: Imjudo (tremelimumab-actl)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Imjudo label DailyMed has published, from AstraZeneca Pharmaceuticals LP, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 10
  • Sections changed, version 14 to 15: 3

What changed from version 14 to version 15

Dec 19, 2025 to Sep 7, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Dosage and administrationChanged ยท punctuation or symbols only
  2. Warnings and precautionsChanged ยท 25 words added, 3 removed
  3. Clinical studiesChanged ยท 18 words added, 14 removed

Dosage and administration

Changedpunctuation or symbols only
83 unchanged lines
Cycle 1:
โ€ขInfuse IMJUDO over one hour. One to two hours after completion of IMJUDO infusion, infuse durvalumab over one hour. One to two hours after completion of durvalumab infusion, administer platinum-based chemotherapy.
Subsequent Cycles:
1 unchanged line

Warnings and precautions

Changed25 words added, 3 removed
83 unchanged lines
Endocrine: Hypoparathyroidism.
Other (hematologicHematologic/immune)Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, and immune thrombocytopenia.
Other: Myocarditis-Myositis-Myasthenia Gravis (or Myasthenia-Like) Overlap Syndrome, reported as the co-occurrence of either two or all three adverse reactions.
5.2 Infusion-Related Reactions
9 unchanged lines

Clinical studies

Changed18 words added, 14 removed
34 unchanged lines
Patients were randomized 1:1:1 to receive IMJUDO in combination with durvalumab and platinum-based chemotherapy according to the regimens listed below, durvalumab and platinum-based chemotherapy (an unapproved regimen for metastatic NSCLC), or platinum-based chemotherapy. The evaluation of efficacy for metastatic NSCLC relied on comparison between:
โ€ขIMJUDO 75 mg (or 1mg1 mg/kg for patients < 30kg30 kg) with durvalumab 1,500 mg and platinum-based chemotherapy every 3 weeks for 4 cycles, followed by durvalumab 1,500 mg every 4 weeks as a single agent. A fifth dose of IMJUDO 75 mg (or 1mg1 mg/kg for patients < 30kg30 kg) was given at Week 16 in combination with durvalumab dose 6.
โ€ขPlatinum-based chemotherapy every 3 weeks as monotherapy for 4 cycles. Patients could receive an additional 2 cycles (a total of 6 cycles post-randomization), as clinically indicated, at Investigatorโ€™s discretion.
Patients received IMJUDO and durvalumab in combination with one of the following platinum-based chemotherapy regimens:
โ€ขNon-squamous NSCLC
โ€ขNon-squamous NSCLC โ€ขPemetrexed 500 mg/m2 with carboplatin AUC 5-6 or cisplatin 75 mg/m2 every 3 weeks for 4 cycles
โ€ขSquamous NSCLC
โ€ขSquamous NSCLC โ€ขGemcitabine 1,000 or 1,250 mg/m2 on Days 1 and 8 with cisplatin 75 mg/m2 or carboplatin AUC 5-6 on Day 1 every 3 weeks for 4 cycles
โ€ขNon-squamous and Squamous NSCLC
โ€ขNon-squamous and Squamous NSCLC โ€ขNab-paclitaxel 100 mg/m2 on Days 1, 8, and 15 with carboplatin AUC 5-6 on Day 1 every 3 weeks for 4 cycles
IMJUDO was given up to a maximum of 5 doses. Durvalumab and histology-based pemetrexed continued every 4 weeks until disease progression or unacceptable toxicity. Administration of durvalumab monotherapy was permitted beyond disease progression if the patient was clinically stable and deriving clinical benefit as determined by the Investigator. Patients with disease progression during durvalumab monotherapy were given the option to be retreated with 4 additional cycles of IMJUDO in combination with durvalumab. Tumor assessments were performed at Week 6, Week 12, and then every 8 weeks thereafter.
19 unchanged lines

Unchanged: Indications and usage, Dosage forms and strengths, Contraindications, Adverse reactions, Use in specific populations, Description, Clinical pharmacology, Nonclinical toxicology, How supplied, Patient counseling information, Medication guide, Package/label principal display panel.

Every version

10 versions of set 6690679c-be2f-4588-a2e4-89fff74dd6be, newest first.
VersionPublished on DailyMedCompareSPL file
15Sep 7, 2026Shown belowDownload .zip
14Dec 19, 2025With version 11Download .zip
11Aug 2, 2024With version 10Download .zip
10May 17, 2024With version 9Download .zip
9Feb 6, 2024With version 8Download .zip
8Feb 5, 2024With version 7Download .zip
7Jun 27, 2023With version 6Download .zip
6Nov 17, 2022With version 5Download .zip
5Oct 31, 2022With version 3Download .zip
3Oct 27, 2022First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.